Skip to main content
Gilead8-K: Acquisition announced

Gilead Enters Definitive Agreement to Acquire PepStar's Oral IL-23R Inhibitor Program

Source: Autobound Signal API · 68 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Gilead announced a definitive agreement to acquire the oral IL-23R inhibitor program from PepStar Therapeutics Limited, including lead asset HCXT-2001.

Source

SEC EDGAROct 29, 2026

Current report (Form 8-K)

Gilead 8-K

Filing excerpt

Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program.

sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
8-K: Acquisition announced

What this signalsIntegration work after a deal often opens needs for new systems and services.

Form
8-K
Fiscal year end
10/29
Filed
Oct 29, 2026

The full record

From the Signal API record

Details

CIK
882095
Accession number
0000882095-26-000037
Filing year
2026
Why it matters
Integration needs coming
Signal category
Strategic

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 3, 2026
signal_type
sec-8k
signal_subtype
acquisitionAnnounced

Use this data

Get every 8-K signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/164b13a2-9cbb-4308-976c-17a79992f2f2 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "164b13a2-9cbb-4308-976c-17a79992f2f2",
  "signal_type": "sec-8k",
  "signal_subtype": "acquisitionAnnounced",
  "detected_at": "2026-11-03T07:08:14.975+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "detail": "Gilead announced a definitive agreement to acquire the oral IL-23R inhibitor program from PepStar Therapeutics Limited, including lead asset HCXT-2001. This acquisition may drive integration needs and clinical research outsourcing opportunities.",
    "summary": "Gilead Enters Definitive Agreement to Acquire PepStar's Oral IL-23R Inhibitor Program",
    "excerpts": "Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htm",
    "filing_date": "2026-10-29",
    "filing_year": 2026,
    "fiscal_year_end": "10/29",
    "sales_relevance": "Integration needs coming",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.